A Vaccine Against Over-Expectations?

It is encouraging that the development of AZD1222 (the vaccine being trialled by Oxford University and AstraZeneca) is looking positive but these are still early days (https://www.theguardian.com/world/2020/oct/27/covid-vaccine-uk-oxford-university-astrazeneca-works-in-all-ages-trials-suggest). The actual results have not yet been published but the vaccine is said to generate an antibody response in all age groups trialled thus far, including a category of 'ancients' (over 56). Although a few tests have been done in the over 70s, they currently seem to be quite limited. The more mature categories encouragingly showed a low incidence of side-effects. Older people (70+), with their declining immune systems, should be a main focus for any vaccination programme, as this is where most of the Covid-19 deaths have been concentrated. If all goes well, the vaccine might be 'wheeled out' in 2021 (an early Christmas present seems less likely). There is, of course, no guarantee that vaccine-induced elevations of antibodies will give long-term protection against an infections with sars Covid2. We just have to wait and see.